Fighting brain cancer with CAR-T cells: Targeting zombie cells to improve therapy
Dr Ashley Vardon at the University of Birmingham hopes to find a way to effectively fight diffuse midline glioma with new immunotherapies.
Developing a new drug for the treatment of ALT-positive cancers
Dr Jon Elkins and Dr Anna Rose at the University of Oxford hope to develop a new drug which will affect vital ALT-positive cancer cell processes.
Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Investigating a new type of drug that can inhibit the growth and survival of neuroblastoma and other childhood cancers
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Creating advanced models to test new treatments for malignant rhabdoid tumours
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.
Finding the best way to make two cancer-targeting T cells for the price of one
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.
A new approach to deliver chemotherapy directly into brain tumours
Professor Rylie Green at Imperial College London will test a device that can deliver chemotherapy directly to brain tumours, sparing healthy cells.
Finding kinder drugs in genetically matched cell models for childhood leukaemia
Professor Alex Thompson and his team at the University of Nottingham aim to learn more about leukaemia to support the development of kinder treatments.
Making CAR-T cells that can rest to improve their cancer-fighting ability
Professor John Anderson’s team at University College London Great Ormond Street Institute of Child Health aim to revolutionise CAR T-cell therapy for solid tumours.
Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Unravelling the behaviour of individual lymphoma cells to find out why the cancer can relapse or resist treatment
Professor Suzanne Turner will investigate the behaviour of individual lymphoma cells in order to find out why treatments fail.
Finding the most beneficial dose of fludarabine to optimise CAR-T therapy
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.